Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

21. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial.

Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. 26575060 2015 11 20 2015 12 24 2017 01 23 1538-3598 314 19 2015 Nov 17 JAMA JAMA Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. 2034-44 10.1001/jama.2015.13896 Many preschool children (...) develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed. To evaluate if early administration of azithromycin, started prior to the onset of severe LRTI symptoms, in preschool children with recurrent severe LRTIs can prevent the progression of these episodes. A randomized, double-blind, placebo-controlled, parallel-group

JAMA2015 Full Text: Link to full Text with Trip Pro

22. Azithromycin in early infancy and pyloric stenosis

Azithromycin in early infancy and pyloric stenosis 25687145 2015 03 03 2015 04 28 2017 01 13 1098-4275 135 3 2015 Mar Pediatrics Pediatrics Azithromycin in early infancy and pyloric stenosis. 483-8 10.1542/peds.2014-2026 Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS). The risk with azithromycin remains unknown. We evaluated the association between exposure to oral azithromycin and erythromycin and subsequent development of IHPS (...) . A retrospective cohort study of children born between 2001 and 2012 was performed utilizing the military health system database. Infants prescribed either oral erythromycin or azithromycin as outpatients in the first 90 days of life were evaluated for development of IHPS. Specific diagnostic and procedural codes were used to identify cases of IHPS. A total of 2466 of 1 074 236 children in the study period developed IHPS. Azithromycin exposure in the first 14 days of life demonstrated an increased risk of IHPS

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

23. Azithromycin (Zedbac®)

Azithromycin (Zedbac®) Azithromycin (Zedbac®) Azithromycin (Zedbac®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Azithromycin (Zedbac®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 1914. 2014 Authors' conclusions Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder

Health Technology Assessment (HTA) Database.2015

24. Azithromycin (Zedbac) - for the treatment of community-acquired pneumonia (CAP)

Azithromycin (Zedbac) - for the treatment of community-acquired pneumonia (CAP) Final Appraisal Recommendation Advice No: 1914 – July 2014 Azithromycin (Zedbac ® ) 500 mg powder for solution for infusion Limited submission by Aspire Pharma Ltd Additional notes: ? The company submission included evidence for azithromycin (Zedbac ® ) in the treatment of CAP due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. No evidence was provided for azithromycin (...) /patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Azithromycin (Zedbac ® ) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac ® ) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community- acquired pneumonia (CAP) due

All Wales Medicines Strategy Group2014

25. Azithromycin (Zedbac) - the treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID)

Azithromycin (Zedbac) - the treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID) Published 07 April 2014 Product Update azithromycin 500mg powder for solution for infusion (Zedbac ® ) (No. 950/14) Aspire Pharma Limited 07 March 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission: azithromycin (Zedbac ® ) is accepted for use within NHS Scotland. Indication under review: the treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID) due to susceptible organisms in adult patients where initial intravenous therapy is required. Consideration should be given to official guidance regarding the appropriate use of antibacterial agents. This is the first intravenous formulation of azithromycin to be made available in the UK

Scottish Medicines Consortium2014

26. Cohort study: Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain

Cohort study: Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain Article Text Therapeutics Cohort study Azithromycin associated with a reduction

Evidence-Based Medicine (Requires free registration)2014 Full Text: Link to full Text with Trip Pro

27. Non-cystic fibrosis bronchiectasis: long-term azithromycin

Non-cystic fibrosis bronchiectasis: long-term azithromycin Non-cystic fibrosis bronchiectasis: long-term Non-cystic fibrosis bronchiectasis: long-term azithrom azithromy ycin cin Evidence summary Published: 25 November 2014 nice.org.uk/guidance/esuom38 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in November 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE (...) websites for up-to-date information. Summary Two randomised controlled trials (BAT: Altenburg J et al. 2013; n=89 and EMBRACE: Wong C et al. 2012; n=141) found that, compared with placebo, azithromycin reduced the rate of pulmonary exacerbations needing antibiotics in adults with non-cystic fibrosis bronchiectasis over 6 to 12 months. However, the evidence for other outcomes is unclear and the improvement in exacerbations must be balanced against the risk of experiencing adverse events and

National Institute for Health and Clinical Excellence - Advice2014

28. Cystic fibrosis: long-term azithromycin

Cystic fibrosis: long-term azithromycin Cystic fibrosis: long-term azithrom Cystic fibrosis: long-term azithromy ycin cin Evidence summary Published: 25 November 2014 nice.org.uk/guidance/esuom37 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in November 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information (...) . Summary A Cochrane review (10 studies, n=959) assessed the use of long-term azithromycin for cystic fibrosis. Six studies (n=836) had a low risk of bias. Various dosing regimens were used, the most common being 250-500 mg 3 times weekly. In 4 studies (n=549), treatment with azithromycin statistically significantly improved forced expired volume in 1 second (FEV 1 ; the primary outcome) over 6 months compared with placebo. Azithromycin doubled the rate of being free of exacerbations over 6 months

National Institute for Health and Clinical Excellence - Advice2014

29. Azithromycin

Azithromycin USE OF AZITHROMYCIN IN PREGNANCY 0344 892 0909 USE OF AZITHROMYCIN IN PREGNANCY (Date of issue: September 2012 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Azithromycin is a macrolide antibiotic derived from erythromycin. There are few published data on the use of azithromycin (...) in human pregnancy however the currently available data do not indicate that the use of azithromycin in pregnancy is associated with an increased risk of malformations or adverse pregnancy outcome. An increased incidence of cardiovascular defects and pyloric stenosis have been suggested for macrolides as a class, although causality has not been established conclusively. Where possible, the results of culture and sensitivity tests should be available before making a treatment choice. If treatment

UK Teratology Information Service2014

30. Azithromycin use in paediatrics: A practical overview

Azithromycin use in paediatrics: A practical overview Azithromycin use in paediatrics: A practical overview | Position statements and practice points | Azithromycin use in paediatrics: A practical overview | Canadian Paediatric Society Protecting and promoting the health and well-being of children and youth CPS Member Login | Who We Are What We Do Get Involved Education/CPD Publications Careers > Share PRACTICE POINT Azithromycin use in paediatrics: A practical overview Posted: Jun 7 2013 (...) Reaffirmed: Feb 1 2016 The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) Philippe Ovetchkine, Michael J Rieder; Canadian Paediatric Society , Paediatr Child Health 2013;18(6):311-3 Abstract Azithromycin is an antibiotic that is commonly prescribed for upper and lower respiratory tract infections in children. While it has proven benefits, some concerns

Canadian Paediatric Society2013

31. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. IMPORTANCE: Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis. OBJECTIVE: To determine the efficacy of macrolide maintenance treatment for adults with non-CF bronchiectasis. DESIGN, SETTING, AND PARTICIPANTS (...) : The BAT (Bronchiectasis and Long-term Azithromycin Treatment) study, a randomized, double-blind, placebo-controlled trial conducted between April 2008 and September 2010 in 14 hospitals in The Netherlands among 83 outpatients with non-CF bronchiectasis and 3 or more lower respiratory tract infections in the preceding year. INTERVENTIONS: Azithromycin (250 mg daily) or placebo for 12 months. MAIN OUTCOME MEASURES: Number of infectious exacerbations during 12 months of treatment. Secondary end points

JAMA2013

32. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. 23532241 2013 03 27 2013 03 28 2016 10 17 1538-3598 309 12 2013 Mar 27 JAMA JAMA Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. 1251-9 10.1001/jama.2013.1937 Macrolide antibiotics have been shown beneficial (...) in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis. To determine the efficacy of macrolide maintenance treatment for adults with non-CF bronchiectasis. The BAT (Bronchiectasis and Long-term Azithromycin Treatment) study, a randomized, double-blind, placebo-controlled trial conducted between April 2008 and September 2010 in 14 hospitals in The Netherlands among 83 outpatients with non-CF bronchiectasis and 3 or more lower

JAMA2013

33. Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial

Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial 22748516 2012 11 22 2013 01 22 2012 11 22 1097-6833 161 6 2012 Dec The Journal of pediatrics J. Pediatr. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial. 1104-8 10.1016 (...) /j.jpeds.2012.05.053 S0022-3476(12)00611-7 To test the hypothesis that azithromycin reduces the length of hospitalization and oxygen requirement in infants with acute viral bronchiolitis (AB). We performed a randomized, double-blinded, placebo-controlled trial in southern Brazil, from 2009 to 2011. Infants (<12 months of age) hospitalized with AB were recruited in 2 hospitals. Patients were randomized to receive either azithromycin or placebo, administered orally, for 7 days. At enrollment, clinical

EvidenceUpdates2012

34. Azithromycin dihydrate (Azyter) - Local antibacterial treatment of conjunctivitis

Azithromycin dihydrate (Azyter) - Local antibacterial treatment of conjunctivitis Published 09 July 2012 Statement of Advice: azithromycin dihydrate (Azyter ®) 15 mg/g, eye drops, solution in single-dose container (No: 804/12) Spectrum Thea Pharmaceuticals Limited 08 June 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation Azithromycin dihydrate (Azyter®) is not recommended for use within NHS Scotland. Indication under review: Local antibacterial treatment

Scottish Medicines Consortium2012

35. Azithromycin and the risk of cardiovascular death.

Azithromycin and the risk of cardiovascular death. BACKGROUND: Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death. METHODS: We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication (...) , excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score-matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions). RESULTS: During 5 days of therapy, patients taking azithromycin, as compared with those

NEJM2012 Full Text: Link to full Text with Trip Pro

36. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. 22901887 2012 08 20 2012 09 14 2015 06 16 1474-547X 380 9842 2012 Aug 18 Lancet (London, England) Lancet Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. 660-7 10.1016/S0140-6736(12)60953-2 Azithromycin is a macrolide antibiotic with anti-inflammatory (...) and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis. We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past

Lancet2012

37. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.

Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. 22192488 2012 01 16 2012 02 07 2015 06 16 1474-547X 379 9811 2012 Jan 14 Lancet (London, England) Lancet Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. 143-51 10.1016/S0140-6736(11)61515-8 In trachoma control programmes, azithromycin is distributed to treat the strains (...) of chlamydia that cause ocular disease. We aimed to compare the effect of annual versus twice-yearly distribution of azithromycin on infection with these strains. We did a cluster-randomised trial in 24 subdistricts in northern Ethiopia, which we randomly assigned to receive annual or twice-yearly treatment for all residents of all ages. Random assignment was done with the RANDOM and SORT functions of Microsoft Excel. All individuals were offered their assigned treatment of a single, directly observed

Lancet2012

38. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial.

Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. 22240407 2012 01 30 2012 02 09 2015 06 16 1474-547X 379 9813 2012 Jan 28 Lancet (London, England) Lancet Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. 342-7 10.1016/S0140-6736(11)61624-3 Yaws--an endemic (...) treponematosis and, as such, a neglected tropical disease--is re-emerging in children in rural, tropical areas. Oral azithromycin is effective for syphilis. We assessed the efficacy of azithromycin compared with intramuscular long-acting penicillin to treat patients with yaws. We did an open-label, non-inferiority, randomised trial at Lihir Medical Centre, Papua New Guinea, between Sept 1, 2010, and Feb 1, 2011. Children aged 6 months to 15 years with a serologically confirmed diagnosis of yaws were randomly

Lancet2012

39. WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever).

WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). BACKGROUND: Review status: Current question - no update intended. Azithromycin treatments are included in the review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). (Thaver D, Zaidi AKM, Critchley JA, Azmatullah A, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database of Systematic Reviews 2008, Issue 4. Art (...) . No.: CD004530. DOI: 10.1002/14651858.CD004530.pub3.) This latter review is being updated, and will be published in late 2011.Enteric fever (typhoid and paratyphoid fever) is potentially fatal. Infection with drug-resistant strains of the causative organism Salmonella enterica serovar Typhi or Paratyphi increases morbidity and mortality. Azithromycin may have better outcomes in people with uncomplicated forms of the disease. OBJECTIVES: To compare azithromycin with other antibiotics for treating

Cochrane2011

40. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis

Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis 2010. DAR No 7. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 7. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis DAR No 7. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial (...) or trachomal conjunctivitis Content tools Share it Similar efficacy at a higher cost Azithromycin in topical ophthalmic form is indicated in the treatment of susceptible strains of bacterial conjunctivitis and trachoma related conjunctivitis caused by Chlamydia trachomatis. The majority of purulent bacterial conjunctivitis cure spontaneously, and azithromycin has shown a similar efficacy and safety profile to tobramycin. There are no trials comparing other antibiotics. Although its posology is much more

Drug and Therapeutics Bulletin of Navarre (Spain)2011